Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results

Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials.



This is for informational purposes only. You should consult your clinical textbook for advising your patients.